ACM
EVMN

ADAR1 Capital Management’s Evommune Inc EVMN Stock Holding History

ADAR1 Capital Management’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.23M Hold
184,062
– – 0.25% 85
2025
Q4 		$3.15M Buy
+184,062
New +$3.46M 0.23% 75

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ADAR1 Capital Management's EVMN Position: Q1 2026 in Review

ADAR1 Capital Management held its Evommune Inc (EVMN) position steady in Q1 2026 at 184,062 shares worth $4.23M. The position accounts for 0.25% of the portfolio, ranked #85.

ADAR1 Capital Management first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • ADAR1 Capital Management held 184,062 shares of Evommune Inc worth $4.23M as of Q1 2026.
  • ADAR1 Capital Management left its Evommune Inc share count unchanged in Q1 2026.
  • Evommune Inc made up 0.25% of ADAR1 Capital Management's portfolio in Q1 2026, its #85 holding.
  • ADAR1 Capital Management first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.